Elevai LabsELAB
ELAB
About: PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
Employees: 3
0
Funds holding %
of 7,310 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
123% more capital invested
Capital invested by funds: $85.5K [Q4 2024] → $191K (+$105K) [Q1 2025]
5.89% more ownership
Funds ownership: 1.21% [Q4 2024] → 7.1% (+5.89%) [Q1 2025]
0% more funds holding
Funds holding: 4 [Q4 2024] → 4 (+0) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for ELAB.
Financial journalist opinion
Based on 5 articles about ELAB published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
PMGC Holdings Inc. Signs Non-Binding LOI to Acquire CNC Aerospace Manufacturer Generating $4.5 Million in Annual Revenue
Serves Multiple Tier-1 Aerospace Clients AS9100 and ISO 9001-Certified CNC Manufacturer NEWPORT BEACH, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (the “Company,” “PMGC,” “we,” or “us”), a diversified public holding company, today announced that it has entered into a non-binding Letter of Intent (“LOI”) to acquire a U.S.-based, CNC machining company specializing in manufacturing high-complexity components for the aerospace and defense sectors.
Neutral
GlobeNewsWire
2 weeks ago
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies
NEWPORT BEACH, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital”), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), today issued a public statement urging Alaunos Therapeutics, Inc. (NASDAQ: TCRT) to accept and act upon the term sheet previously facilitated through a leading Wall Street Bank.
Neutral
GlobeNewsWire
2 weeks ago
Northstrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Diseases
Northstrive Biosciences and Yuva Biosciences previously announced a collaboration leveraging MitoNova™, YuvaBio's proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions. Phase II of this collaboration involves compiling a selection of small molecule candidates that promote mitochondrial health in obesity and cardiac diseases.
Neutral
GlobeNewsWire
2 weeks ago
PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based AS9100D & ISO 9001:2015 Certified CNC Machine Shop Serving Aerospace, Defense, and Industrial Markets for over 35 years
PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based AS9100D & ISO 9001:2015 Certified US-Based CNC Machine Shop Serving Aerospace, D
Neutral
GlobeNewsWire
3 weeks ago
PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Electronics Manufacturing Company
Acquisition Target Specializes in High-Precision Electrical and Mechanical Assembly, Including Printed Circuit Board Manufacturing for Commercial and Industrial Customers Across the U.S.A. PMGC's second pending acquisition since April, demonstrates that its M&A strategy is well underway, with additional deals expected this year.
Neutral
GlobeNewsWire
1 month ago
NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia
NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Re
Neutral
GlobeNewsWire
1 month ago
PMGC Holdings Inc. Announces Filing of Quarterly Report on Form 10-Q
NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has filed its Quarterly Report on Form 10-Q (“Quarterly Report”) for the three months ended March 31, 2025, with the U.S. Securities and Exchange Commission (“SEC”).
Neutral
GlobeNewsWire
1 month ago
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)
NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our,” or “us”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. (Nasdaq: TCRT).
Neutral
GlobeNewsWire
2 months ago
RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health
NEWPORT BEACH, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced the filing of four novel patent applications for its two candidates EL-22 and EL-32.
Neutral
GlobeNewsWire
2 months ago
Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial
Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Pha
Charts implemented using Lightweight Charts™